RESULTS
The reference diameter was 2.33þ/-0.30 mm, the lesion length was 23.8þ/-13.7 mm, and the acute gain was 1.55þ/-0.6 mm. The restenosis rate was just 2.8%, the target lesion revascularization rate was just 1.0%, and the late lumen loss was 0.22þ/-0.4 mm.
CONCLUSION Based on the 8-month angiographic data, restenosis and target lesion revascularization rate were low. 2.25 mm PtCr-EES is considered effective in treating very small vessel lesions. The patients were divided into two groups according to the type of ostial lesion. (RCAos group; n¼40, LMos group; n¼34). Study endpoints were a composite of major adverse cardiacevents (MACE), including all-cause death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR) for 5years.
RESULTS There was no significant difference between two groups in baseline characteristics. Cumulative MACE for 5 years in patients with aorto-ostial lesion was higher in RCAos group than LMos group (37.5% vs. 14.7%, p¼0.028). In RCAos group, the incidences of all-cause death (15.0% vs. BACKGROUND Percutaneous coronary intervention (PCI) with drug eluting stent (DES) in small vessel coronary disease (SVD, diameter <2.8 mm) is the standard of care with low target lesion revascularization (TLR) rate of 6-9%. Recently, drug coated balloon (DCB) has been used to treat de-novo SVD with promising result. We studied the efficacy and safety of drug coated balloon-only angioplasty (DCBA) in SVD amongst high-risk patients.
METHODS
We retrospectively analyzed the outcome of consecutive patients who underwent PCI to de-novo SVD with DCB or DES sized 2.5 mm in 2013 with 1 year follow up data.
RESULTS One hundred and twenty (120) patients were intervened with DCBA (100% Sequent Please, BBraun), male 83.3%, mean age 62 AE 11.5 years old; 48% had diabetes mellitus, 70% had hyperlipidemia, 75.6% had hypertension and 26% had history of smoking. Three quarter of the patients presented with acute coronary syndrome (ACS), unstable angina pectoris/NSTEMI (59.2%) and STEMI (25.8%).
In the DCBA arm, the most common target vessel was LCX (39%), followed by LAD (36%) and RCA (24%). On average, 1.38 DCB was used per patient. Mean diameter or DCB was 2.26 AE 0.25 mm and mean length was 16.3 AE 4.1 mm.
In the same period, 24 patients had DES implantation using stents diameter 2.5mm. The demographics of the DES patients were not significantly different from the DCBA group. In total 26 devices were used. Mean diameter of the DES was 2.44 AE 0.1 mm with mean length of 22.6 AE 8.4 mm.
Despite the predominantly ACS presentation, patients treated with DCBA had shorter duration of DAPT than the DES group (8.2 months vs. 12 months, p<0.0001).
At 1 year, 10 MACEs were observed at DEBA arm (8.33%), consisting of 4 MIs (3%) and 5 TLRs (4.16%). In patients treated with DES, there was 1 TLR (4.1%) at 1 year, without any other MACE. No death or major bleeding was found in either group during 1-year period.
CONCLUSION DCBA has similar TLR at 1 year compared to second generation DES implantation (4.16% vs. 4.16%, respectively, p ¼ 0.74) in treating SVD in a high-risk group of patients. The DAPT duration was also shorter using DCBA. 
